Journal Wrap | API-CAT, ALPACA, DAPA-TAVI, PROLONG-ANG3
The hottest research from various peer-reviewed journals – handpicked weekly by the ACC.
Extended anticoagulant therapy with a reduced-dose of apixaban was noninferior to extended therapy with a full-dose of apixaban in preventing recurrent venous thromboembolism (VTE) in patients with active cancer and proximal deep-vein thrombosis (DVT) or pulmonary embolism (PE), based on findings from the API-CAT trial presented at ACC.25 and simultaneously published in NEJM. In addition, patients receiving the reduced dose experienced a lower incidence of clinically relevant bleeding.
The novel extended-duration small interfering RNA lepodisiran reduced mean serum concentrations of lipoprotein(a) (Lp[a]) from 60 to 180 days after being administered subcutaneously, according to results presented from the ALPACA study during a Featured Clinical Research session at ACC.25 and simultaneously published in the NEJM.
The SGLT2 inhibitor dapagliflozin was superior to standard care alone in decreasing rates of all-cause mortality or worsening heart failure (HF) in older adults with aortic stenosis undergoing TAVI, resulting in a 28% relative risk reduction, according to results from the DAPA-TAVI study presented during a Late-Breaking Clinical Trial session during ACC.25 and simultaneously published in the NEJM.
Solbinsiran at the 400 mg dose reduced apolipoprotein B (apoB) concentration in patients with mixed dyslipidemia, according to research presented during a Featured Clinical Research session at ACC.25 and simultaneously published in The Lancet. The novel treatment is a GalNAc-conjugated small interfering RNA (siRNA) targeting hepatic ANGPTL3 protein expression.
Clinical Topics: Anticoagulation Management, Diabetes and Cardiometabolic Disease, Dyslipidemia, Heart Failure and Cardiomyopathies, Pulmonary Hypertension and Venous Thromboembolism, Valvular Heart Disease, Vascular Medicine, Anticoagulation Management and Venothromboembolism, Advanced Lipid Testing, Lipid Metabolism, Nonstatins, Statins, Acute Heart Failure
Keywords: Cardiology Magazine, ACC Publications, ACC25, ACC Annual Scientific Session, Venous Thromboembolism, Anticoagulants, RNA, Small Interfering, Lipoprotein(a), Ezetimibe, Sodium-Glucose Transporter 2 Inhibitors, Aortic Valve Stenosis, Heart Failure, Dyslipidemias
